UBS Increases Target Price for SH PHARMA (02607) to HK$15.2, Maintains "Buy" Rating

Stock News04-01

UBS released a research report indicating that SH PHARMA (02607) reported a 3% year-on-year increase in total revenue last year, reaching RMB 284 billion. Net profit rose by 25.7% year-on-year to RMB 5.72 billion, while recurring net profit fell by 26.7% year-on-year to RMB 2.98 billion, largely in line with expectations. The firm adjusted its profit forecasts for SH PHARMA for the years 2026 to 2028, ranging from a 1% decrease to a 3% increase. The target price was raised from HK$15 to HK$15.2, with a "Buy" rating maintained. UBS highlighted that, considering SH PHARMA's strategic positioning, diversified business operations, and competitive advantages in rapidly growing sectors, it anticipates the company's growth during the "15th Five-Year Plan" period will outpace its pharmaceutical distribution peers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment